- Home
- CERS vs RCKT Comparison
CERS vs RCKT Comparison
Compare CERS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- RCKT
- Stock Information
- Founded
- CERS 1991
- RCKT 1999
- Country
- CERS United States
- RCKT United States
- Employees
- CERS N/A
- RCKT N/A
- Industry
- CERS EDP Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- RCKT Health Care
- Exchange
- CERS Nasdaq
- RCKT Nasdaq
- Market Cap
- CERS 277.2M
- RCKT 328.6M
- IPO Year
- CERS 1997
- RCKT N/A
- Fundamental
- Price
- CERS $1.39
- RCKT $3.14
- Analyst Decision
- CERS Strong Buy
- RCKT Buy
- Analyst Count
- CERS 2
- RCKT 13
- Target Price
- CERS $3.50
- RCKT $14.79
- AVG Volume (30 Days)
- CERS 1.1M
- RCKT 3.6M
- Earning Date
- CERS 08-05-2025
- RCKT 08-08-2025
- Dividend Yield
- CERS N/A
- RCKT N/A
- EPS Growth
- CERS N/A
- RCKT N/A
- EPS
- CERS N/A
- RCKT N/A
- Revenue
- CERS $185,144,000.00
- RCKT N/A
- Revenue This Year
- CERS $20.97
- RCKT N/A
- Revenue Next Year
- CERS $15.55
- RCKT $608.87
- P/E Ratio
- CERS N/A
- RCKT N/A
- Revenue Growth
- CERS 13.06
- RCKT N/A
- 52 Week Low
- CERS $1.12
- RCKT $2.19
- 52 Week High
- CERS $2.54
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- CERS 48.50
- RCKT 49.02
- Support Level
- CERS $1.35
- RCKT $3.03
- Resistance Level
- CERS $1.47
- RCKT $3.54
- Average True Range (ATR)
- CERS 0.07
- RCKT 0.21
- MACD
- CERS -0.01
- RCKT 0.09
- Stochastic Oscillator
- CERS 22.73
- RCKT 49.37
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.